CFOROTCServices-Medical LaboratoriesFiscal year ends December 31
CapForce Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$4.03+0.53 (+15.14%)
Close on Oct 19, 2026
- Market cap
- $50.33M
- P/E (TTM)
- 0.7
- Dividend yield
- –
CapForce Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q4 25 | Q3 25 | Q2 25 | Q2 24 | Q4 23 | Q3 23 | Q2 23 | Q1 23 | Q4 22 | Q3 22 | Q2 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Listing sponsorship services [Member] | $50.00M | $26.20M | $0 | $4.00M | – | – | – | – | – | – | – | – | 100.0% | +1150.0% |
| Product [Member] | – | – | – | – | $28.00K | $990.52K | $558.97K | $439.67K | $410.90K | $279.43K | $359.11K | $889.27K | – | – |
| Service [Member] | – | – | – | – | – | $40.91K | $47.14K | $44.00K | $21.67K | $78.12K | $31.02K | $20.57K | – | – |
| Collaboration revenue [Member] | – | – | – | – | – | $38.29K | $92.92K | $252.46K | $480.87K | $364.09K | $58.59K | $57.36K | – | – |
By region
| Revenue | Q2 26 | Q4 25 | Q3 25 | Q2 25 | Q2 24 | Q4 23 | Q3 23 | Q2 23 | Q1 23 | Q4 22 | Q3 22 | Q2 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Domestic [Member] | – | – | – | – | $28.00K | $154.12K | $142.72K | $266.31K | $114.95K | $104.69K | $135.86K | $123.66K | – | – |
| International [Member] | – | $26.20M | $0 | $4.00M | – | $915.60K | $556.31K | $469.82K | $798.50K | $616.94K | $312.86K | $843.55K | – | – |
From the segment and revenue-disaggregation notes of CapForce's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.